1. Home
  2. MITQ vs HSCS Comparison

MITQ vs HSCS Comparison

Compare MITQ & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

HOLD

Current Price

$0.54

Market Cap

5.4M

ML Signal

HOLD

Logo Heart Test Laboratories Inc.

HSCS

Heart Test Laboratories Inc.

HOLD

Current Price

$2.39

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITQ
HSCS
Founded
N/A
2007
Country
United States
United States
Employees
N/A
12
Industry
Telecommunications Equipment
Medical Specialities
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
6.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MITQ
HSCS
Price
$0.54
$2.39
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
41.3K
156.4K
Earning Date
05-15-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,139,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$58.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$1.63
52 Week High
$1.66
$3.93

Technical Indicators

Market Signals
Indicator
MITQ
HSCS
Relative Strength Index (RSI) 39.08 51.36
Support Level $0.42 $2.11
Resistance Level $0.66 $2.82
Average True Range (ATR) 0.05 0.23
MACD -0.01 -0.05
Stochastic Oscillator 7.35 42.57

Price Performance

Historical Comparison
MITQ
HSCS

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

About HSCS Heart Test Laboratories Inc.

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

Share on Social Networks: